DSGN
Design Therapeutics Inc
12.40$
-6.1%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | -100.0% | -100.0% | – | – | – | – | |
| – | +202.3% | +2,480.0% | +261.2% | +15.2% | +11.0% | +4.4% | |
| – | – | – | – | – | – | – | |
| – | +266.4% | +308.9% | +96.2% | +17.4% | -22.3% | +33.3% | |
| – | +129.4% | +342.8% | +71.7% | +11.3% | -14.6% | +12.8% | |
| – | +348.2% | +319.0% | +88.6% | +14.9% | -20.4% | +27.6% | |
| – | – | – | – | – | – | – | |
| – | – | – | +1,474.2% | – | – | – | |
| – | – | – | – | – | – | – | |
| – | -244.8% | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.